Climate change and clinical trials: what World Environment Day 2026 means

World Environment Day, observed every June 5, is the United Nations’ largest annual platform for environmental awareness. The 2026 theme is climate change, and the global campaign asks governments, organizations, and individuals to step up under the banner #NowForClimate.

The connection between climate change and clinical trials runs in two directions. Climate change is shifting the health conditions that clinical research needs to study, from heat-related illness to changes in infectious disease patterns. At the same time, clinical trials themselves carry a measurable environmental footprint, and the industry has begun to systematically measure and reduce it.

This blog explains what that means in 2026. Where do the emissions come from in a typical clinical trial? What is being done about them? And how are the changes showing up for research sites and for the people who take part in studies?

Why climate change is a clinical research issue

A warming planet is not only an environmental story. It is also a public health story.

Rising temperatures are linked to more frequent heat-related illness, worsening respiratory conditions tied to air quality, shifts in how some infectious diseases spread, and growing mental health pressures linked to extreme weather events and displacement. These shifts feed directly into clinical research. The conditions clinical trials need to study are themselves being shaped by the climate.

A clinical trial is a structured research study that tests how safe and effective a new medicine, device, or other approach is in people. As climate-sensitive conditions become more common, researchers are designing more studies to address them. That is the first connection between climate change and clinical trials, and it is the one most readers see in the news.

You can read more on the public health role of research in How Clinical Trials Contribute to Public Health.

The second connection is less visible. Trials themselves use travel, freight, lab equipment, paper, and electricity. All of those produce emissions. World Environment Day 2026 is a useful moment to look at what that environmental cost looks like and what the research industry is doing about it.

The carbon footprint of a clinical trial

Until recently, the environmental impact of clinical research was rarely measured. That has started to change.

A peer-reviewed analysis published in a leading medical journal looked at roughly 350,000 trials registered globally and estimated that clinical research produced about 27.5 million metric tonnes of greenhouse gas emissions between 2020 and 2021. To put that in context, it is roughly equivalent to the annual carbon emissions of a major city.

At the level of a single study, the numbers are also striking. Industry analysis estimates that one large late-stage trial, the kind that tests an investigational product in thousands of participants across many countries, can generate up to about 3,000 metric tonnes of carbon dioxide equivalent (a standard unit that combines different greenhouse gases into one comparable number). That is roughly the annual emissions of around 176 people in the United States.

Healthcare as a whole, including hospitals, drug manufacturing, and clinical research, accounts for an estimated 5 percent of global greenhouse gas emissions.

Where do those emissions come from inside a clinical trial? The biggest contributors are usually:

• Participant travel to and from study visits
• Travel by sponsor and CRO monitors between sites, offices, and meetings (CROs, or contract research organizations, are companies that run trials on behalf of sponsors)
• Shipping of investigational products, lab samples, and supplies
• Paper-based documentation and printed materials
• Electricity used in labs, freezers, and study equipment

Most of these emissions sit in what sustainability teams call “Scope 3,” meaning they are indirect and scattered across many vendors and locations. That has historically made them difficult to track. Newer measurement tools are starting to change that.

How the research industry is responding in 2026

The push to reduce clinical trial emissions has accelerated since 2024. A few markers from the last 18 months stand out.

In early 2025, an industry coalition of large pharmaceutical sponsors, contract research organizations, and service providers launched a free carbon calculator designed specifically for clinical trials. The tool gives sponsors a standardized way to estimate where their emissions are coming from before they design a study.

A separate industry initiative committed major pharmaceutical companies to reporting emissions on Phase II and Phase III trials starting from 2025. (Phase II trials test safety and early signs of effectiveness in a few hundred people. Phase III trials test the same in much larger groups before regulatory approval.)

Individual sponsors have set their own targets. After a full life-cycle review of its trials, one large pharmaceutical company estimated that it could reduce trial-related emissions by up to 74 percent by 2030. Separate industry analysis found that just five categories of activity drove almost 80 percent of one sponsor’s clinical trial carbon footprint, which means a relatively small number of changes can produce outsized results.

Standardized measurement is the foundation. Once sponsors and sites can see where the emissions sit, the design choices follow. Many of those design choices overlap with another trend already well underway in clinical research: making trials less burdensome for participants and easier to run remotely.

Where decentralized and hybrid trial designs fit in

A decentralized clinical trial uses remote and digital tools so that participants do not need to travel to a research site for every visit. A hybrid trial combines some in-person visits at a site with remote elements, such as video calls with the study team, home delivery of the investigational product, and at-home data collection through wearable devices or mobile apps.

These trial designs were developed primarily to make participation easier and to reach people who live far from a research site. They also happen to reduce the carbon footprint of the study itself. Fewer participant trips, fewer monitor visits, less printing, and centralized digital records all cut emissions across the categories described in the previous section.

There is a caveat worth flagging. Digital tools have their own environmental cost, including the energy used by data centers, devices, and networks. Industry researchers have started studying whether the climate benefits of decentralized trial elements consistently outweigh that digital footprint. The early signal is that they do, but the picture is still being measured.

You can read more on the access side of this trend in How Decentralized Trials May Improve Research Access.

DecenTrialz is a platform that connects people to clinical trials they may be eligible for. Matching is AI-assisted (AI stands for artificial intelligence, which is used here to narrow which studies might fit a person’s situation), a nurse pre-screens each potential participant before referral, and the research team running the study makes all final eligibility and enrollment decisions. The platform’s design supports the lower-burden, remote-friendly direction the industry is moving in, which is also the direction that reduces emissions. You can start a search at decentrialz.com.

What this means at research sites

Research sites, the hospitals, clinics, and research centers that actually run studies, are increasingly being asked about sustainability by sponsors and CROs. Several practical levers are now well documented.

Reducing participant travel through hybrid visits is the largest single opportunity at most sites. Where a protocol allows, replacing in-person follow-up visits with telehealth check-ins or in-home assessments cuts both participant burden and site-visit emissions.

Electronic source documents, sometimes called eSource, reduce paper use and make remote monitoring possible. Remote monitoring, in turn, cuts the travel emissions tied to sponsor and CRO oversight visits.

Local lab partnerships shorten the distance that biological samples have to travel. A blood sample collected near the participant’s home and processed at a regional lab has a smaller transport footprint than one shipped to a central lab across the country.

Reviewing supply chains is the harder, longer-term lever. Sites that work with sponsors to optimize drug shipment routes, reduce over-ordering, and use lower-emission couriers are positioning themselves well as sponsors begin to formally track Phase II and Phase III emissions.

None of these changes compromise safety, data quality, or regulatory oversight. The Good Clinical Practice standards that govern clinical trials apply with the same force in a hybrid or decentralized design as they do in a fully on-site one.

What this means for participants

For people who are thinking about joining a clinical trial, or who are already enrolled in one, the sustainability shift is mostly visible as fewer in-person visits and more remote interaction with the study team.

A few practical changes a participant might notice in 2026 compared with five years ago:

• More telehealth visits with the study coordinator or study doctor
• Investigational products shipped directly to the participant’s home rather than picked up at the research site
• At-home data collection using a smartphone app, a wearable device, or a self-administered questionnaire
• Electronic informed consent and electronic signature instead of paper packets at the first visit
• Fewer trips to the research site for routine measurements that can be done remotely

These changes are about reducing participant burden first. The lower environmental footprint is a benefit that comes along with them.

What does not change: participant rights, safety monitoring, informed consent, and the role of the study team in overseeing every step of the study. A participant joining a trial in 2026 has the same protections as someone who joined a more traditional in-person trial in 2018.

If you want a closer look at how these designs work from the participant side, see Virtual Clinical Trials: What Patients Need to Know.

There is one more connection worth noting. As climate change shifts which health conditions are most common, the kinds of trials open for enrollment also shift. Studies focused on heat-related illness, respiratory conditions tied to air quality, certain infectious diseases, and climate-linked mental health conditions are becoming more visible. People with those conditions may find more research options available than was the case a decade ago.

World Environment Day 2026 frames climate change as something that requires action from everyone, not only governments and large industries. The #NowForClimate campaign points the same direction.

For clinical research, that translates into practical work already underway. Sponsors are measuring trial emissions and setting reduction targets. Industry coalitions are building shared tools so measurement is consistent across the field. Sites are adopting hybrid designs, eSource, and remote monitoring. Participants are seeing trials that fit better into their lives.

None of this changes the core purpose of a clinical trial, which is to find out whether a new medicine, device, or approach is safe and effective. It simply reduces the environmental cost of finding that out.

If you are considering joining a clinical study, you can begin a search at decentrialz.com. A nurse pre-screens each potential participant before any referral to a research team, and the team running the study makes all final decisions about eligibility and enrollment.